GPR35通路激活驱动肿瘤微环境血管生成
该研究探讨GPR35通路在自发性和结肠炎相关结肠癌肿瘤微环境中的作用。巨噬细胞Gpr35缺失显著减少肿瘤生长;GPR35通过Na/K-ATP酶依赖的离子泵和Src激活促进血管生成和基质金属蛋白酶活性,并可被GPR35特异性pepducin抑制。携带UC和PSC风险变异的人iPSC来源巨噬细胞上清通过增强血管生成因子释放刺激管腔形成。
要点
- 巨噬细胞GPR35缺失显著减少炎症相关和自发性肿瘤模型的肿瘤生长
- GPR35通过Na/K-ATP酶依赖离子泵和Src激活促进血管生成与基质金属蛋白酶活性
- GPR35特异性pepducin可选择性抑制该通路
核心结论
- GPR35通路激活通过两条独立途径促进肿瘤生长:直接增强表达该受体的上皮细胞增殖,以及协调巨噬细胞创建肿瘤许可环境。
研究设计与样本
- 在巨噬细胞上缺乏GPR35的小鼠中进行自发性结肠癌或结肠炎相关癌症模型,并通过生化与功能实验评估肿瘤相关巨噬细胞的作用。
主要发现
- 巨噬细胞上的GPR35是肿瘤生长的强效放大器,通过刺激新生血管生成和肿瘤组织重塑发挥作用。
- 巨噬细胞中Gpr35缺失在炎症相关肿瘤模型和由突变抑癌基因腺瘤性息肉病 coli 引起的自发性肿瘤模型中均显著减少肿瘤生长。
- GPR35通过Na/K-ATP酶依赖的离子泵和Src激活促进新生血管生成和基质金属蛋白酶活性,并被GPR35特异性pepducin选择性抑制。
- 携带UC和PSC风险变异的人诱导多能干细胞来源巨噬细胞的上清通过增强血管生成因子释放刺激管腔形成。
关键数值与推荐
- PSC在70%的病例中与炎症性肠病相关;GPR35的T108M超形态变异增加PSC和UC风险。
- GPR35缺失减少小鼠自发性癌症和结肠炎相关癌症模型中的肿瘤数量。
临床怎么用
- GPR35通路可能作为肿瘤微环境中血管生成的治疗靶点,GPR35特异性pepducin具有选择性抑制潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Primary sclerosing cholangitis (PSC) is in 70% of cases associated with inflammatory bowel disease. The hypermorphic T108M variant of the orphan G protein-coupled receptor GPR35 increases risk for PSC and ulcerative colitis (UC), conditions strongly predisposing for inflammation-associated liver and colon cancer. Lack of GPR35 reduces tumour numbers in mouse models of spontaneous and colitis associated cancer. The tumour microenvironment substantially determines tumour growth, and tumour-associated macrophages are crucial for neovascularisation. We aim to understand the role of the GPR35 pathway in the tumour microenvironment of spontaneous and colitis-associated colon cancers. DESIGN: Mice lacking GPR35 on their macrophages underwent models of spontaneous colon cancer or colitis-associated cancer. The role of tumour-associated macrophages was then assessed in biochemical and functional assays. RESULTS: Here, we show that GPR35 on macrophages is a potent amplifier of tumour growth by stimulating neoangiogenesis and tumour tissue remodelling. Deletion of Gpr35 in macrophages profoundly reduces tumour growth in inflammation-associated and spontaneous tumour models caused by mutant tumour suppressor adenomatous polyposis coli. Neoangiogenesis and matrix metalloproteinase activity is promoted by GPR35 via Na/K-ATPase-dependent ion pumping and Src activation, and is selectively inhibited by a GPR35-specific pepducin. Supernatants from human inducible-pluripotent-stem-cell derived macrophages carrying the UC and PSC risk variant stimulate tube formation by enhancing the release of angiogenic factors. CONCLUSIONS: Activation of the GPR35 pathway promotes tumour growth via two separate routes, by directly augmenting proliferation in epithelial cells that express the receptor, and by coordinating macrophages' ability to create a tumour-permissive environment.
引用
- Pagano E, Elias JE, Schneditz G, et al. Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment. Gut. 2021. PMID: 33758004. doi:10.1136/gutjnl-2020-323363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。